DOCSLIB.ORG

Annual Report and Financial Statements 2018 Highlights

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report and Financial Statements 2018 Highlights MEDICLINIC ANNUAL REPORT AND FINANCIAL STATEMENTS AND FINANCIAL STATEMENTS REPORT ANNUAL 201 8 ANNUAL REPORT AND FINANCIAL STATEMENTS for the year ended 31 March 2018 HIGHLIGHTS SUCCEEDING IN THE TURNAROUND OF THE ABU DHABI BUSINESS with continued strong performance in Southern Africa and Dubai 740 000+ INPATIENT ADMISSIONS across all operating divisions as the demand for quality healthcare services continues to increase £245M – SIGNIFICANT ONGOING CAPEX INVESTMENT across the Group supporting patient experience, clinical excellence, maintenance, upgrades and expansion REVENUE UP 4% to £2 870m; up 3% in constant currency terms ADJUSTED EBITDA UP 3% to £515m; flat in constant currency EARNINGS LOSS OF £492M impacted by non-cash Hirslanden and Spire impairment charges and other exceptional items ADJUSTED EARNINGS PER SHARE UP 1% to 30.0 pence TOTAL DIVIDEND FOR THE YEAR 7.90 PENCE The Group uses adjusted income statement reporting as non-IFRS measures in evaluating performance. Refer to the Financial Review on page 29 for an explanation. CONTENTS STRATEGIC REPORT 3 Report Profile Business Overview 4 Performance Highlights 6 Chairman’s Statement 10 At a Glance 12 Business Model 14 Our Strategy, Progress and Aims 18 Investment Case 19 Five-Year Summary Performance and Future Outlook 20 Chief Executive Officer’s Review 24 Financial Review 33 Value Added Statement 34 Clinical Services Overview Risk Management 44 Risk Management, Principal Risks and Uncertainties 50 Viability Statement Divisional Reviews 52 Divisional Review – Switzerland 56 Divisional Review – Southern Africa 60 Divisional Review – UAE Non-financial Performance 68 Sustainable Development Highlights GOVERNANCE AND REMUNERATION 85 Chairman’s Introduction 86 Board of Directors 90 Senior Management 93 Corporate Governance Statement 112 Nomination Committee Report 116 Clinical Performance and Sustainability Committee Report 120 Audit and Risk Committee Report 130 Directors’ Remuneration Report 160 Statement of Directors’ Responsibilities FINANCIAL STATEMENTS 162 Group Financial Statements 248 Company Financial Statements ADDITIONAL INFORMATION 262 Shareholder Information 266 Company Information 267 Glossary IBC Forward-looking Statements EXPERTISE YOU CAN TRUST. Mediclinic is focused on providing acute care, specialist-orientated, multi-disciplinary healthcare services. Our core purpose is to enhance the quality of life of our patients by providing comprehensive, high-quality healthcare services in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, doctors and funders of healthcare in each of its markets. MEDICLINIC HAS THREE OPERATING DIVISIONS IN SWITZERLAND, SOUTHERN AFRICA AND 75 THE UNITED ARAB EMIRATES With continuing regulatory HOSPITALS changes during the year in Switzerland, Hirslanden continues to focus on adapting to the evolving outpatient environment whilst delivering 28 SWITZERLAND cost savings and operational CLINICS efficiencies. Read more about Hirslanden AR from page 52. Mediclinic Southern Africa, once again, delivered steady 10 684 revenue growth and managed its cost base despite pressure PATIENT BEDS SOUTHERN on patient volumes in the AFRICA current environment. Read more about Mediclinic AR Southern Africa from page 56. 411 The Middle East division reached an inflection point THEATRES this year with a strong second half performance delivering marginal improvement in revenue and adjusted EBITDA margin for the year; succeeding 31 504 with the turnaround of the Abu UNITED ARAB Dhabi business and laying the EMPLOYEES EMIRATES foundation for further growth. Read more about Mediclinic AR Middle East from page 60. CONTRIBUTION TO CONTRIBUTION TO CONTRIBUTION TO REVENUE ADJUSTED EBITDA* ADJUSTED EARNINGS* Switzerland (1%) (2%) 1% 16% Southern Africa 22% 20% Middle East TOTAL £2 870M TOTAL £515M TOTAL £221M 47% 48% 48% 37% Corporate 31% 33% United Kingdom AR * The Group uses adjusted income statement reporting as non-IFRS measures in evaluating performance. Refer to the Financial Review on page 24 for an explanation and for a reconciliation to the equivalent IFRS measures. OUR STRATEGIC OBJECTIVES Mediclinic seeks to generate long-term shareholder value through: • putting Patients First; • improving Group and operational effi ciencies; • pursuing attractive growth opportunities; and • leveraging our global scale, while continuing to invest in employees, information and communications technology AR “WE ARE and analytics. Read more about Our Strategy, Progress and Aims from page 14. DETERMINED TO MEET AND FURTHER INFORMATION This Annual Report is published as part of a suite of reports, as listed below. The icons EXCEED THE below are used as a cross-referencing tool to refer to the relevant pages of these reports EXPECTATIONS or within this Annual Report. AR Annual Report and Financial OF OUR Statements 2018 CSR PATIENTS IN Clinical Services Report 2018 SDR EVERY MARKET Sustainable Development Report 2018 AGM WHERE WE Notice of Annual General Meeting 2018 These reports are available on the Company’s OPERATE.” website at www.mediclinic.com from the date of distribution of this Annual Report and the Company’s Notice of Annual General Meeting by no later than 22 June 2018. DANIE MEINTJES CHIEF EXECUTIVE GLOSSARY OFFICER Please refer to the glossary of terms used in AR this report from page 267. APPROVAL OF ANNUAL REPORT This Annual Report and Financial Statements, including the Strategic Report herein, was approved by the Board on 23 May 2018. Edwin Hertzog Non-executive Chairman 23 May 2018 MEDICLINIC | ANNUAL REPORT 2018 1 2 MEDICLINIC | ANNUAL REPORT 2018 REPORT PROFILE Scope, boundary and reporting cycle This Annual Report and Financial Statements (“Annual Report”) of Mediclinic International plc (the “Company” or “Mediclinic”) presents the fi nancial results, and the economic, social and environmental performance of the Mediclinic Group for the fi nancial year ended 31 March 2018 (the “reporting period”), REPORT STRATEGIC REPORT PROFILE REPORT and covers the Company’s operations in Switzerland, Southern Africa and the United Arab Emirates (the “Group”). Reporting principles The information in this Annual Report is deemed to be useful and relevant to our stakeholders, with due regard to their expectations through continuous engagement, or that the Board believes may infl uence the perception or decision-making GOVERNANCE AND REMUNERATION GOVERNANCE of our stakeholders. The information provided aims to provide our stakeholders with an understanding of the Group’s fi nancial, social, environmental and economic impacts to enable them to evaluate the ability of Mediclinic to create and sustain value. This Annual Report was prepared in accordance with the International Financial Reporting Standards, the LSE Listing Rules, the JSE Listings Requirements, the UK Corporate Governance Code, and the UK Companies Act (including the Companies, Partnerships and Group (Accounts and Non-Financial STRATEGIC Reporting) Regulations 2016 aimed at improving the transparency of companies regarding non- fi nancial and diversity information), where relevant. FINANCIAL STATEMENTS REPORT The Company complied with all the provisions of the UK Corporate Governance Code, other AR “The Group’s strategic focus ensures that it than the exceptions explained in the Corporate consistently delivers high-quality healthcare and Governance Statement on page 93 of this Annual optimal patient experience across the operating Report. The Company’s reporting on sustainable development included in this report, supplemented divisions in Switzerland, Southern Africa and the SDR by the Sustainable Development Report, available Middle East.” on the Company’s website at www.mediclinic.com, was done in accordance with the GRI Sustainability Danie Meintjes Reporting Standards 2016 and the non-fi nancial Chief Executive Offi cer reporting regulations referred to above. External audit and assurance ADDITIONAL INFORMATION The Company’s annual fi nancial statements and the AR Group’s consolidated annual fi nancial statements were audited by the Group’s independent external auditors, PricewaterhouseCoopers LLP, in accordance with International Standards of Auditing (UK). The Group follows various other voluntary external accreditation, certifi cation and assurance initiatives, complementing the Group’s combined assurance AR model, as reported on in the Risk Management section of this Annual Report. The Group believes that this adds to the transparency and reliability of information reported to our stakeholders. MEDICLINIC | ANNUAL REPORT 2018 3 PERFORMANCE HIGHLIGHTS GROUP FINANCIAL RESULTS OPERATIONAL HIGHLIGHTS STRONG FINANCIAL POSITION REVENUE (£’m) The strong financial position of the Group supported the overall performance of the three divisions in 2018. In Switzerland, Hirslanden was faced with a number of regulatory changes that came into effect during the year and the division will need to continue adapting to 2 870 the evolving outpatient environment whilst delivering cost savings 2 749 and operational efficiencies. The division recognised an impairment 2 107 charge on intangible assets and properties of £644m. The Southern 1 977 1 892 Africa division, once again, produced steady revenue growth and managed its cost base despite pressure on patient volumes in the 2014 2015 2016 2017 2018 current environment. The Middle East division reached an inflection point this year with a strong second half performance delivering marginal improvement
Load more

Recommended publications
  • Mediclinic Middle East and Al Noor Hospitals Group Investor Roadshow 14
    MEDICLINIC MIDDLE EAST INVESTOR SITE VISIT 14 - 16 JUNE 2016 DISCLAIMER This presentation has been prepared by Mediclinic International plc (the "Company"). No representation or warranty (express or implied) of any nature is given nor is any responsibility or liability of any kind accepted by the Company or any of its directors, officers, employees, advisers, representatives or other agents, with respect to the truthfulness, completeness or accuracy of any information, projection, representation or warranty (expressed or implied), omissions, errors or misstatements in this presentation, or any other written or oral statement provided. In particular, no responsibility or liability is or will be accepted and no representation or warranty is or is authorised to be given as to the accuracy, reliability or reasonableness of any forward looking statement including any future projections, management targets, estimates or assessments of future prospects contained in this presentation, or of any assumption or estimate on the basis of which they have been given (which may be subject to significant business, economic or competitive uncertainties and contingencies beyond the control of the management of the Company) . Any such forward-looking statements have not been independently audited, examined or otherwise reviewed or verified. All views expressed in this presentation are based on financial, economic, market and other conditions prevailing as of the date of this presentation. The Company does not undertake to provide access to any additional information or to update any future projections, management targets, estimates or assessment of future prospects or any other forward-looking statements to reflect events that occur or circumstances that arise after the date of this presentation, or to correct any inaccuracies in this presentation which may become apparent.
    [Show full text]
  • Parker Review
    Ethnic Diversity Enriching Business Leadership An update report from The Parker Review Sir John Parker The Parker Review Committee 5 February 2020 Principal Sponsor Members of the Steering Committee Chair: Sir John Parker GBE, FREng Co-Chair: David Tyler Contents Members: Dr Doyin Atewologun Sanjay Bhandari Helen Mahy CBE Foreword by Sir John Parker 2 Sir Kenneth Olisa OBE Foreword by the Secretary of State 6 Trevor Phillips OBE Message from EY 8 Tom Shropshire Vision and Mission Statement 10 Yvonne Thompson CBE Professor Susan Vinnicombe CBE Current Profile of FTSE 350 Boards 14 Matthew Percival FRC/Cranfield Research on Ethnic Diversity Reporting 36 Arun Batra OBE Parker Review Recommendations 58 Bilal Raja Kirstie Wright Company Success Stories 62 Closing Word from Sir Jon Thompson 65 Observers Biographies 66 Sanu de Lima, Itiola Durojaiye, Katie Leinweber Appendix — The Directors’ Resource Toolkit 72 Department for Business, Energy & Industrial Strategy Thanks to our contributors during the year and to this report Oliver Cover Alex Diggins Neil Golborne Orla Pettigrew Sonam Patel Zaheer Ahmad MBE Rachel Sadka Simon Feeke Key advisors and contributors to this report: Simon Manterfield Dr Manjari Prashar Dr Fatima Tresh Latika Shah ® At the heart of our success lies the performance 2. Recognising the changes and growing talent of our many great companies, many of them listed pool of ethnically diverse candidates in our in the FTSE 100 and FTSE 250. There is no doubt home and overseas markets which will influence that one reason we have been able to punch recruitment patterns for years to come above our weight as a medium-sized country is the talent and inventiveness of our business leaders Whilst we have made great strides in bringing and our skilled people.
    [Show full text]
  • The U.A.E. Healthcare Sector an Update: January 2018
    The U.A.E. Healthcare Sector An Update: January 2018 The U.S.-U.A.E. Business Council is the premier business organization dedicated to advancing bilateral commercial relations. By leveraging its extensive networks in the U.S. and in the region, the U.S.-U.A.E. Business Council provides unparalleled access to senior decision makers in business and government with the aim of deepening bilateral trade and investment. U.S.-U.A.E. Business Council 505 Ninth Street, NW Suite 6010 Washington D.C. +202.863.7285 [email protected] usuaebusiness.org 1 INTRODUCTION The U.A.E.’s healthcare sector has dramatically expanded over the past four decades. At the time of the U.A.E.’s founding in 1971, the country had just seven hospitals and 12 health centers. As of 2015, according to the latest figures from the U.A.E. statistics authority, the U.A.E. had 126 public and private hospitals with a combined capacity of over 12,000 beds.1 U.S. companies and citizens have played an important role in this growth story, as best symbolized by the Oasis Hospital in Al Ain. In 1960, U.S. missionaries Drs. Pat and Marian Kennedy built this hospital – the U.A.E.’s first – in a mud-block guesthouse donated by the late U.A.E. President Sheikh Zayed bin Sultan Al Nahyan.2 Over the next 50 years, this hospital birthed more than 90,000 babies, including members of Abu Dhabi’s ruling family.3 Moreover, it retained strong connections with that family, which funded the hospital’s expansion earlier this decade.4 As the U.A.E.
    [Show full text]
  • MTS Bondspro
    Press Release 30 May 2018 FTSE UK Index Series Quarterly Review June 2018 GVC Holdings and Ocado Group to join FTSE 100 Mediclinic International and G4S to enter FTSE 250 in rebalance FTSE Russell, the global index provider, confirms today that GVC Holdings and Ocado Group will be joining the FTSE 100 Index. In the rebalance, Mediclinic International and G4S will leave the FTSE 100 Index and enter the FTSE 250 Index. The rules-driven, impartial quarterly reviews ensure the indexes continue to portray an accurate reflection of the market they represent, and form an essential component to the management of the indexes. The FTSE 250 Index will see the following changes (in alphabetical order), in addition to the amendments described above. Entering FTSE 250 Index Exiting FTSE 250 Index Energean Oil & Gas Marstons Integrafin Holdings Pets At Home Group Laird Purecircle Premier Oil Woodford Patient Capital Trust FTSE Russell operates a reserve list for the FTSE 100 Index, to be used in the event of a corporate action occurring between reviews e.g. merger, acquisition, delisting or suspension. In such cases, the reserve list constituent with the largest market capitalisation (on the date of the corporate action) will replace the outgoing constituent. With immediate effect, the following reserve list for FTSE 100 will be used: Weir Group Rightmove Mediclinic International Spirax-Sarco Engineering Kaz Minerals Wood Group (John) All changes from this review will be implemented at the close of business on Friday, 15 June 2018 and take effect from the start of trading on Monday, 18 June 2018.
    [Show full text]
  • Press Release
    PRESS RELEASE Geneva, 9 September 2019 HIRSLANDEN CLINIQUE LA COLLINE JOINS LAVER CUP AS OFFICIAL MEDICAL PARTNER Hirslanden Clinique La Colline has been selected by the Laver Cup to become its official medical partner in Geneva, September 20-22, 2019. The Laver Cup today announced its official medical partnership with Hirslanden Clinique La Colline, who’s recently inaugurated Sports Medicine Center has been recognized by Swiss Olympic as Sport Medical Center and professional osteopathy services in the tennis field. Hirslanden Clinique La Colline will be working with Laver Cup and ATP Physiotherapists to provide dedicated treatment and massage therapy services during the tournament. “We are delighted to become the official medical partner of the Laver Cup in Geneva. With our combined expertise in sports medicine, orthopedics and osteopathy, our goal is to enable Team Europe and Team World to showcase the best of their abilities in Geneva. Performance is a matter of preparation and discipline”, says Gilles Rufenacht, Director of Hirslanden Clinique La Colline in Geneva. “We look forward to working with the professional team at Hirslanden at the Laver Cup in Geneva. Their experienced practitioners will be a key asset for all the players, and will ensure both teams have access to the services they need to prepare for what promises to be an incredible weekend of tennis action,” Laver Cup CEO Steve Zacks said. “ Information: Hirslanden Clinique La Colline Laver Cup Magali Dauwalder Prue Ryan Head of Communications Head of Public Relations T +41 79 107 56 76 +61 419 308 369 [email protected] [email protected] www.hirslanden.ch Hirslanden Private Hospital Group As of 31 March 2019, the Hirslanden Private Hospital Group consists of 18 hospitals in 11 cantons, many of which have an integrated outpatient surgery centre and emergency department.
    [Show full text]
  • Linklaters Provides You with Market Leading Practices, Strong Teams
    خدماتنا القانونية املعروضة Our legal services offering الرشق األوسط Middle East Linklaters provides you with market leading practices, strong teams focused on all the main legal areas and a regional geographical footprint within an international network. Linklaters is a leading global law firm with Linklaters’ offices in Dubai and Abu Linklaters is acknowledged as a market 29 offices in 19 countries and has more Dhabi act as a hub for the firm’s activities leader for corporate/M&A, capital markets, top ranked practices globally than its in the MENA region, and our team has banking, project finance, Islamic finance UK or U.S. headquartered competitors*. established itself as one of the few firms and international arbitration matters. Our global approach, commitment to in the region capable of advising on cross- The offices also have dedicated sector excellence and depth of experience border transactions. Our fully-integrated specialists in the energy, infrastructure, mean that we have built a strong track international network means that we petrochemicals, financial institutions, record of advising a range of government are able to draw on our market-leading financial sponsor and telecommunications organisations and privately-owned expertise across various offices, practices sectors. The firm’s track record includes businesses, acting on matters throughout and sector teams when required, while acting on some of the most significant and the region, including in the United Arab providing a seamless service to our innovative deals, as well as some of the Emirates, Saudi Arabia, Qatar, Kuwait, clients. Our clients instruct us on their most high profile disputes that the region Iraq, Iran, Bahrain, Oman, Jordan, most complex deals, whether it’s operating has seen in recent years.
    [Show full text]
  • COVID-19 - ESSKA Guidelines and Recommendations for Resuming Elective Surgery Caroline Mouton, Michael Hirschmann, Matthieu Ollivier, Romain Seil, Jacques Menetrey
    COVID-19 - ESSKA guidelines and recommendations for resuming elective surgery Caroline Mouton, Michael Hirschmann, Matthieu Ollivier, Romain Seil, Jacques Menetrey To cite this version: Caroline Mouton, Michael Hirschmann, Matthieu Ollivier, Romain Seil, Jacques Menetrey. COVID- 19 - ESSKA guidelines and recommendations for resuming elective surgery. Journal of Experimental Orthopaedics, Springer Verlag, 2020, 7 (1), pp.28. 10.1186/s40634-020-00248-4. hal-03175930 HAL Id: hal-03175930 https://hal.archives-ouvertes.fr/hal-03175930 Submitted on 22 Mar 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License Mouton et al. Journal of Experimental Orthopaedics (2020) 7:28 Journal of https://doi.org/10.1186/s40634-020-00248-4 Experimental Orthopaedics REVIEW Open Access COVID-19 - ESSKA guidelines and recommendations for resuming elective surgery Caroline Mouton1,2, Michael T. Hirschmann3, Matthieu Ollivier4, Romain Seil1,2 and Jacques Menetrey5,6* Abstract The roadmap to elective surgery resumption after this COVID-19 pandemic should be progressive and cautious. The aim of this paper was to give recommendations and guidelines for resuming elective orthopedic surgery in the safest environment possible.
    [Show full text]
  • IPO Prospectus
    IMPORTANT: You must read the following disclaimer before continuing. This electronic transmission applies to the attached document and you are therefore advised to read this disclaimer carefully before reading, accessing or making any other use of the attached document. In accessing the attached document, you agree to be bound by the following terms and conditions, including any modifications to them from time to time, each time you receive any information from us as a result of such access. You acknowledge that this electronic transmission and the delivery of the attached document is confidential and intended for you only and you agree you will not forward, reproduce or publish this electronic transmission or the attached document to any other person. This electronic transmission and the attached document comprises an advertisement for the purposes of paragraph 3.3.2R of the Prospectus Rules made under Part VI of the Financial Services and Markets Act 2000 (“FSMA”) and has been prepared solely in connection with the proposed application to the Financial Conduct Authority (the “FCA”) for all of the ordinary shares (the “Shares”) of Al Noor Hospitals Plc (to be renamed Al Noor Hospitals Group Plc) (the “Company”) to be admitted to the premium listing segment of the Official List maintained by the FCA and to the London Stock Exchange plc for the Shares to be admitted to trading on its main market for listed securities (“Admission”) and the proposed offer of Shares to certain institutional and professional investors (the “Offer”). The information in the attached document, which is in draft form, is subject to updating, completion, revision, verification and amendment.
    [Show full text]
  • Stoxx® Europe 600 Index
    STOXX® EUROPE 600 INDEX Components1 Company Supersector Country Weight (%) NESTLE Food & Beverage CH 2.51 NOVARTIS Health Care CH 2.02 HSBC Banks GB 2.01 ROCHE HLDG P Health Care CH 1.63 TOTAL Oil & Gas FR 1.49 ROYAL DUTCH SHELL A Oil & Gas GB 1.42 BRITISH AMERICAN TOBACCO Personal & Household Goods GB 1.34 BP Oil & Gas GB 1.31 SIEMENS Industrial Goods & Services DE 1.12 BCO SANTANDER Banks ES 1.08 SAP Technology DE 1.08 ALLIANZ Insurance DE 1.04 BAYER Health Care DE 0.97 BASF Chemicals DE 0.96 SANOFI Health Care FR 0.93 GLAXOSMITHKLINE Health Care GB 0.91 NOVO NORDISK B Health Care DK 0.91 BNP PARIBAS Banks FR 0.89 ASTRAZENECA Health Care GB 0.86 DIAGEO Food & Beverage GB 0.85 DAIMLER Automobiles & Parts DE 0.85 ANHEUSER-BUSCH INBEV Food & Beverage BE 0.84 UNILEVER NV Personal & Household Goods NL 0.84 ASML HLDG Technology NL 0.84 LVMH MOET HENNESSY Personal & Household Goods FR 0.82 VODAFONE GRP Telecommunications GB 0.75 UBS GROUP Banks CH 0.72 PRUDENTIAL Insurance GB 0.69 ING GRP Banks NL 0.69 LLOYDS BANKING GRP Banks GB 0.68 AIRBUS Industrial Goods & Services FR 0.68 UNILEVER PLC Personal & Household Goods GB 0.65 GLENCORE PLC Basic Resources GB 0.65 RIO TINTO Basic Resources GB 0.61 AXA Insurance FR 0.59 VINCI Construction & Materials FR 0.57 INTESA SANPAOLO Banks IT 0.55 RECKITT BENCKISER GRP Personal & Household Goods GB 0.55 BCO BILBAO VIZCAYA ARGENTARIA Banks ES 0.55 L'OREAL Personal & Household Goods FR 0.54 AIR LIQUIDE Chemicals FR 0.54 DEUTSCHE TELEKOM Telecommunications DE 0.54 DANONE Food & Beverage FR 0.53 ZURICH INSURANCE
    [Show full text]
  • FTSE UK 100 ESG Select
    2 FTSE Russell Publications 19 August 2021 FTSE UK 100 ESG Select Indicative Index Weight Data as at Closing on 30 June 2021 Constituent Index weight (%) Country Constituent Index weight (%) Country Constituent Index weight (%) Country 3i Group 0.83 UNITED KINGDOM Halfords Group 0.06 UNITED KINGDOM Prudential 2.67 UNITED KINGDOM 888 Holdings 0.08 UNITED KINGDOM Harbour Energy PLC 0.01 UNITED KINGDOM Rathbone Brothers 0.08 UNITED KINGDOM Anglo American 2.62 UNITED KINGDOM Helical 0.03 UNITED KINGDOM Reckitt Benckiser Group 3.01 UNITED KINGDOM Ashmore Group 0.13 UNITED KINGDOM Helios Towers 0.07 UNITED KINGDOM Rio Tinto 4.8 UNITED KINGDOM Associated British Foods 0.65 UNITED KINGDOM Hiscox 0.21 UNITED KINGDOM River and Mercantile Group 0.01 UNITED KINGDOM Aviva 1.18 UNITED KINGDOM HSBC Hldgs 6.33 UNITED KINGDOM Royal Dutch Shell A 4.41 UNITED KINGDOM Barclays 2.15 UNITED KINGDOM Imperial Brands 1.09 UNITED KINGDOM Royal Dutch Shell B 3.85 UNITED KINGDOM Barratt Developments 0.52 UNITED KINGDOM Informa 0.56 UNITED KINGDOM Royal Mail 0.39 UNITED KINGDOM BHP Group Plc 3.29 UNITED KINGDOM Intermediate Capital Group 0.44 UNITED KINGDOM Schroders 0.29 UNITED KINGDOM BP 4.66 UNITED KINGDOM International Personal Finance 0.02 UNITED KINGDOM Severn Trent 0.44 UNITED KINGDOM British American Tobacco 4.75 UNITED KINGDOM Intertek Group 0.66 UNITED KINGDOM Shaftesbury 0.12 UNITED KINGDOM Britvic 0.19 UNITED KINGDOM IP Group 0.09 UNITED KINGDOM Smith (DS) 0.4 UNITED KINGDOM BT Group 1.26 UNITED KINGDOM Johnson Matthey 0.43 UNITED KINGDOM Smurfit Kappa Group 0.76 UNITED KINGDOM Burberry Group 0.62 UNITED KINGDOM Jupiter Fund Management 0.09 UNITED KINGDOM Spirent Communications 0.11 UNITED KINGDOM Cairn Energy 0.05 UNITED KINGDOM Kingfisher 0.57 UNITED KINGDOM St.
    [Show full text]
  • Al Noor Hospitals Group Plc
    Tuesday 12 August 2014: FOR IMMEDIATE RELEASE Al Noor Hospitals Group Plc. Results for the Six Months Ended 30 June 2014 Good results and a confident outlook London and Abu Dhabi: Al Noor Hospitals Group Plc. (ANHA.L; the "Company" or "Al Noor"), the largest private healthcare service provider in Abu Dhabi, today announces its results for the six months ended 30th June, 2014. Financial summary – All figures in US$ H1 2014 (US $) H1 2013 (US $) Change Revenue $224.8m $179.5m +25.2% Underlying Operating Profit (1) $46.2m $37.7m +22.5% Underlying EBITDA (1,2) $51.7m $41.3m +25.2% EBITDA Margin 23.0% 23.0% 0% Net Cash Position $86.3m $88.0m -1.9% Profit Before Tax $45.6m $24.8m 83.9% Underlying Profit Before Tax $45.6m $34.1m 33.6% Proposed dividend GBP 3.7p per share - - (1) H1 2013 is before IPO costs (2) Represents operating profit after adding back depreciation of $5.5m for H1 2014 and $3.6m for H1 2013. Operational highlights . Outpatient volumes rose 19.7% compared with H1 2013. Inpatient volumes increased 1.2% compared with H1 2013; . Number of Revenue-Generating Doctors increased by 106, a 26.8% increase since H1 2013. Of these, 31 were added in the six months ended 30th June. In the first half of the year, three new medical centers were opened, bringing the total number of centers to 16. 1 Dr. Kassem Alom, CEO, Al Noor Hospitals Group Plc said: “I am pleased to announce that our 2014 first half results have shown further strong profitable growth.
    [Show full text]
  • FTSE Russell Publications
    2 FTSE Russell Publications 19 August 2021 FTSE 250 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Infrastructure 0.43 UNITED Bytes Technology Group 0.23 UNITED Edinburgh Investment Trust 0.25 UNITED KINGDOM KINGDOM KINGDOM 4imprint Group 0.18 UNITED C&C Group 0.23 UNITED Edinburgh Worldwide Inv Tst 0.35 UNITED KINGDOM KINGDOM KINGDOM 888 Holdings 0.25 UNITED Cairn Energy 0.17 UNITED Electrocomponents 1.18 UNITED KINGDOM KINGDOM KINGDOM Aberforth Smaller Companies Tst 0.33 UNITED Caledonia Investments 0.25 UNITED Elementis 0.21 UNITED KINGDOM KINGDOM KINGDOM Aggreko 0.51 UNITED Capita 0.15 UNITED Energean 0.21 UNITED KINGDOM KINGDOM KINGDOM Airtel Africa 0.19 UNITED Capital & Counties Properties 0.29 UNITED Essentra 0.23 UNITED KINGDOM KINGDOM KINGDOM AJ Bell 0.31 UNITED Carnival 0.54 UNITED Euromoney Institutional Investor 0.26 UNITED KINGDOM KINGDOM KINGDOM Alliance Trust 0.77 UNITED Centamin 0.27 UNITED European Opportunities Trust 0.19 UNITED KINGDOM KINGDOM KINGDOM Allianz Technology Trust 0.31 UNITED Centrica 0.74 UNITED F&C Investment Trust 1.1 UNITED KINGDOM KINGDOM KINGDOM AO World 0.18 UNITED Chemring Group 0.2 UNITED FDM Group Holdings 0.21 UNITED KINGDOM KINGDOM KINGDOM Apax Global Alpha 0.17 UNITED Chrysalis Investments 0.33 UNITED Ferrexpo 0.3 UNITED KINGDOM KINGDOM KINGDOM Ascential 0.4 UNITED Cineworld Group 0.19 UNITED Fidelity China Special Situations 0.35 UNITED KINGDOM KINGDOM KINGDOM Ashmore
    [Show full text]